The Global Consortium for Drug-resistant Tuberculosis Diagnostics (GCDD): Design of a multi-site, head-to-head study of three rapid tests to detect extensively drug-resistant tuberculosis

Trials

Volumn 15, Issue 1, 2014, Pages

  Hillery, Naomi ^a   Groessl, Erik J ^a   Trollip, Andre ^b   Catanzaro, Donald ^c   Jackson, Lynn ^d   Rodwell, Timothy C ^d   Garfein, Richard S ^d   Lin, S Y Grace ^e   Eisenach, Kathleen ^f   Ganiats, Theodore G ^a   Park, Daniel ^d   Valafar, Faramarz ^c   Rodrigues, Camilla ^g   Crudu, Valeriu ^h   Victor, Thomas C ^b   Catanzaro, Antonino ^d  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b STELLENBOSCH UNIVERSITY   (South Africa)

^c SAN DIEGO STATE UNIVERSITY   (United States)

^d UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^e CALIFORNIA DEPARTMENT OF PUBLIC HEALTH   (United States)

^f UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

^g P D HINDUJA NATIONAL HOSPITAL   (India)

^h Institute of Phthisiopneumology Microbiology and Morphology Laboratory   (Moldova)

Author keywords

drug resistance; international; multi site; rapid diagnostic tools; tuberculosis; XDR TB

Indexed keywords

AMIKACIN; CAPREOMYCIN; ISONIAZID; KANAMYCIN; MOXIFLOXACIN; OFLOXACIN; RIFAMPICIN; BACTERIAL DNA;

ADOLESCENT; ADULT; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL GENOME; BACTERIAL STRAIN; BACTERIUM ISOLATE; CHILD; COHORT ANALYSIS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DETECTION TIME; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; DRUG RESISTANT TUBERCULOSIS; EPIDEMIOLOGICAL DATA; EXTENSIVELY DRUG RESISTANT TUBERCULOSIS; GENOTYPE; HUMAN; INTERMETHOD COMPARISON; LABORATORY DIAGNOSIS; LINE PROBE ASSAY; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MICROSCOPIC OBSERVATION DRUG SUSCEPTIBILITY ASSAY; MOLECULAR DIAGNOSIS; MULTICENTER STUDY; MYCOBACTERIAL GROWTH INDICATOR TUBE DRUG SUSCEPTIBILITY TEST; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; OUTCOME ASSESSMENT; PATIENT RISK; PHENOTYPE; PREDICTIVE VALUE; PROSPECTIVE STUDY; PUBLIC HEALTH; PYROSEQUENCING; RISK FACTOR; SENSITIVITY AND SPECIFICITY; SEQUENCE BASED ASSAY; TIME; TUBERCULOSIS RAPID TEST; CLINICAL PROTOCOL; CLINICAL TRIAL; COMPARATIVE STUDY; COST BENEFIT ANALYSIS; DRUG EFFECTS; ECONOMICS; EXTENSIVELY DRUG-RESISTANT TUBERCULOSIS; GENETICS; HEALTH CARE COST; INDIA; METHODOLOGY; MICROBIAL SENSITIVITY TEST; MICROBIOLOGY; MOLDOVA; MULTIDRUG RESISTANCE; REPRODUCIBILITY; SOUTH AFRICA; SPUTUM; TIME TO TREATMENT; TUBERCULOSIS, PULMONARY;

CLINICAL PROTOCOLS; COST-BENEFIT ANALYSIS; DNA, BACTERIAL; DRUG RESISTANCE, MULTIPLE, BACTERIAL; EXTENSIVELY DRUG-RESISTANT TUBERCULOSIS; GENOTYPE; HEALTH CARE COSTS; HUMANS; INDIA; MICROBIAL SENSITIVITY TESTS; MOLDOVA; MOLECULAR DIAGNOSTIC TECHNIQUES; MYCOBACTERIUM TUBERCULOSIS; PHENOTYPE; PREDICTIVE VALUE OF TESTS; PROSPECTIVE STUDIES; REPRODUCIBILITY OF RESULTS; RESEARCH DESIGN; SOUTH AFRICA; SPUTUM; TIME FACTORS; TIME-TO-TREATMENT; TUBERCULOSIS, PULMONARY;

EID: 84920190822     PISSN: None     EISSN: 17456215     Source Type: Journal    
DOI: 10.1186/1745-6215-15-434     Document Type: Article

References (23)

1. World Health Organization: Global Tuberculosis Report 2013. Geneva; 2013. [ http://apps.who.int/iris/bitstream/10665/91355/1/9789241564656_eng.pdf ]
2. Dye C, Williams BG: The population dynamics and control of tuberculosis. Science 2010, 328:856-861.
3. Dharmadhikari AS, Basaraba RJ, Van Der Walt ML, Weyer K, Mphahlele M, Venter K, Jensen PA, First MW, Parsons S, McMurray DN, Orme IM, Nardel EA: Natural infection of guinea pigs exposed to patients with highly drug-resistant tuberculosis. Tuberculosis 2011, 91:329-338.
4. Escombe AR, Moore DAJ, Gilman RH, Pan W, Navincopa M, Ticona E, Martinez C, Caviedes L, Sheen P, Gonzalez A, Noakes CJ, Friedland JS, Evans CA: The infectiousness of tuberculosis patients coinfected with HIV. PLoS Med 2008, 5:1387-1397.
5. Fauci AS: Multidrug-resistant and extensively drug-resistant tuberculosis: the National Institute of Allergy and Infectious Diseases Research agenda and recommendations for priority research. J Infect Dis 2008, 197:1493-1498.
6. Rodwell TC, Valafar F, Douglas J, Qian L, Garfein RS, Chawla A, Torres J, Zadorozhny V, Kim MS, Hoshide M, Catanzaro D, Jackson L, Lin G, Desmond E, Rodrigues C, Eisenach K, Victor TC, Ismail N, Crudu V, Gler MT, Catanzaro A: Predicting extensively drug-resistant Mycobacterium tuberculosis phenotypes with genetic mutations. J Clin Microbiol 2014, 52:781-789.
7. Almeida D, Rodrigues C, Udwadia ZF, Lalvani A, Gothi GD, Mehta P, Mehta A: Incidence of multidrug-resistant tuberculosis in urban and rural India and implications for prevention. Clin Infect Dis 2003, 36:152-154.
8. Jenkins HE, Plesca V, Ciobanu A, Crudu V, Galusca I, Soltan V, Serbulenco A, Zignol M, Dadu A, Dara M, Cohen T: Assessing spatial heterogeneity of multidrug-resistant tuberculosis in a high-burden country. Eur Respir J 2013, 42:1291-1301.
9. World Health Organization: Global Tuberculosis Report 2012. Geneva; 2012 [ http://apps.who.int/iris/bitstream/10665/75938/1/9789241564502_eng.pdf ]
10. World Health Organization: Laboratory Services in Tuberculosis Control, Part III: Culture. Geneva; 1998. [ http://whqlibdoc.who.int/hq/1998/WHO_TB_98.258_(part3).pdf ]
11. Lin SYG, Rodwell TC, Victor TC, Rider EC, Pham L, Catanzaro A, Desmond EP: Pyrosequencing for rapid detection of extensively drug-resistant Mycobacterium tuberculosis in clinical isolates and clinical specimens. J Clin Microbiol 2014, 52:475-482.
12. World Health Organization: Policy Guidance on Drug-Susceptibility Testing (DST) of Second-Line Antituberculosis Drugs. Geneva; 2008. [ http://whqlibdoc.who.int/hq/2008/WHO_HTM_TB_2008.392_eng.pdf?ua=1 ]
13. Rodrigues C, Jani J, Shenai S, Thakkar P, Siddiqi S, Mehta A: Drug susceptibility testing of Mycobacterium tuberculosis against second-line drugs using the Bactec MGIT 960 system. Int J Tuberc Lung Dis 2008, 12:1449-1455.
14. Lin SYG, Desmond E, Bonato D, Gross W, Siddiqi S: Multicenter evaluation of Bactec MGIT 960 system for second-line drug susceptibility testing of Mycobacterium tuberculosis complex. J Clin Microbiol 2009, 47:3630-3634.
15. Barnard M, Albert H, Coetzee G, O'Brien R, Bosman ME: Rapid molecular screening for multidrug-resistant tuberculosis in a high-volume public health laboratory in South Africa. Am J Respir Crit Care Med 2008, 177:787-792.
16. Brossier F, Veziris N, Aubry A, Jarlier V, Soudakoff W: Detection by GenoType MTBDR sl test of complex mechanisms of resistance to second-line drugs and ethambutol in multidrug-resistant Mycobacterium tuberculosis complex isolates. J Clin Microbiol 2010, 48:1683-1689.
17. Kiet VS, Lan NT, An DD, Dung NH, Hoa DV, van Vinh CN: Evaluation of the MTBDR sl test for detection of second-line-drug resistance in Mycobacterium tuberculosis. J Clin Microbiol 2010, 48:2934-2939.
18. TM . Mol Biotechnol 2004, 28:129-137.
19. Bravo LTC, Tuohy MJ, Ang C, Destura RV, Mendoza M, Procop GW, Gordon SM, Hall GS, Shrestha NK: Pyrosequencing for rapid detection of Mycobacterium tuberculosis resistance to rifampin, isoniazid, and fluoroquinolones. J Clin Microbiol 2009, 47:3985-3990.
20. Moore DAJ, Evans CAW, Gilman RH, Caviedes L, Coronel J, Vivar A, Sanchez E, Piñedo Y, Saravia JC, Salazar C, Oberhelman R, Hollm-Delgado MG, LaChira D, Escombe R, Friedland JS: Microscopic-observation drug-susceptibility assay for the diagnosis of TB. N Engl J Med 2006, 355:1539-1550.
21. Trollip AP, Moore D, Coronel J, Caviedez L, Klages S, Victor T, Romancenco E, Crudu V, Ajbani K, Vineet VP, Rodrigues C, Jackson RL, Eisenach K, Garfein RS, Rodwell TC, Desmond E, Groessl EJ, Ganiats TG, Catanzaro A: Second-line drug susceptibility breakpoints for Mycobacterium tuberculosis using the MODS assay. Int J Tuberc Lung Dis 2014, 18:227-232.
22. Global Consortium for Drug-resistant Tuberculosis Diagnostics [ http://gcdd.ucsd.edu ]
23. LogMeIn [ https://secure.logmein.com/ ]